George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.00
Bid: 2.80
Ask: 3.20
Change: 0.00 (0.00%)
Spread: 0.40 (14.286%)
Open: 3.00
High: 3.00
Low: 3.00
Prev. Close: 3.00
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman & Co Research: Allergy Therapeutics (AGY): Take an objective view

18 Mar 2019 11:30

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Take an objective view 18-March-2019 / 11:30 GMT/BST


Hardman & Co Research: Take an objective view

AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (AIT), continues to gain market share despite its availability in the EU on a 'named-patient' basis only. The aim of ongoing trials is to move the platform to full registration under the new regulatory framework. Positive outcomes in Phase III allergy trials are notoriously difficult to achieve because the primary endpoint is always subjective. Prudently, AGY included an objective secondary endpoint, which was highly significant, paving the way for regulatory discussion.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/take-an-objective-view/

To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.comFollow us on Twitter @HardmanandCo Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave +44 20 7194 7622 mh@hardmanandco.comdmh@hardmanandco.comgp@hardmanandco.com

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

788559 18-March-2019 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
27th Mar 20247:00 amRNSUpdate on funding
27th Mar 20247:00 amRNSInterim Results for six months ended 31 Dec 2023
12th Mar 20248:59 amRNSVLP Peanut PROTECT Trial Update
12th Mar 20247:00 amRNSVLP Peanut PROTECT Trial Update
11th Mar 20247:00 amRNSAppointment of Shaun Furlong to Board of Directors
8th Mar 20241:49 pmRNSResult of AGM
14th Feb 20247:00 amRNSHalf-Year Trading Update 2024
9th Feb 20243:07 pmRNSNotice of 2023 Annual General Meeting
30th Jan 20247:30 amRNSRestoration - Allergy Therapeutics plc
30th Jan 20247:00 amRNSPublication of Annual Report and Accounts 2023
4th Jan 202412:29 pmRNSTotal Voting Rights
2nd Jan 20247:30 amRNSSuspension - Allergy Therapeutics plc
27th Dec 202312:01 pmRNSAmendment to existing Facility Agreement
15th Dec 202312:48 pmRNSAnnual Report and Accounts Delayed
13th Dec 20234:54 pmRNSPDMR dealing and Total Voting Rights
13th Dec 20237:00 amRNSG306 Phase III trial meets key endpoints
11th Dec 20237:00 amRNSUpdate on funding
1st Dec 20237:00 amRNSTotal Voting Rights
28th Nov 20233:03 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSG306 Grass Phase III trial meets primary endpoint
10th Nov 20232:39 pmRNSForm 8.5 (EPT/RI)
10th Nov 20231:22 pmRNSDirector/PCA Dealing
10th Nov 20231:11 pmRNSHolding(s) in Company
10th Nov 20237:00 amRNSOffer Closure
9th Nov 202310:48 amRNSExercise of Options and Total Voting Rights
9th Nov 20239:24 amRNSForm 8.5 (EPT/RI)
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202310:45 amRNSForm 8.5 (EPT/RI)
7th Nov 202311:10 amRNSForm 8.5 (EPT/RI)
6th Nov 20239:33 amRNSForm 8.5 (EPT/RI)
6th Nov 20237:00 amRNSUpdate on funding
3rd Nov 20239:31 amRNSForm 8.5 (EPT/RI)
2nd Nov 202310:24 amRNSForm 8.5 (EPT/RI)
1st Nov 202310:23 amRNSForm 8.5 (EPT/RI)
31st Oct 20238:30 amRNSForm 8.5 (EPT/RI)
30th Oct 202310:06 amRNSForm 8.5 (EPT/RI)
27th Oct 202311:33 amRNSForm 8.5 (EPT/RI)
26th Oct 202310:07 amRNSForm 8.5 (EPT/RI)
25th Oct 20239:48 amRNSForm 8.5 (EPT/NON-RI)
25th Oct 20238:43 amRNSForm 8.5 (EPT/RI)
24th Oct 20238:29 amRNSForm 8.5 (EPT/RI)
23rd Oct 20238:23 amRNSForm 8.5 (EPT/RI)
20th Oct 20235:17 pmRNSHolding(s) in Company
20th Oct 20239:02 amRNSForm 8.5 (EPT/RI)
19th Oct 20238:38 amRNSForm 8.5 (EPT/RI)
19th Oct 20237:00 amRNSPosting of Offer Document
18th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
17th Oct 202310:31 amRNSForm 8.5 (EPT/RI)
16th Oct 20235:39 pmRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc
16th Oct 20233:03 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.